Nausea can be particularly prominent during the delayed period. Therefore, we performed a metaanalysis of the available randomised evidence to assess the average effect of palonosetron plus one-day dexamethasone (DEX; also called the DEX-sparing strategy) compared with palonosetron plus 3-day DEX for control of chemotherapy-induced nausea and vomiting (CINV), focusing on delayed nausea. | Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy A meta-analysis of randomised evidence
